Compare Merck & Co., Inc. (MRK) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nasdaq Inc — how do they compare? Merck & Co., Inc. trades at $132.68 (market cap $327.94B), while Nasdaq Inc trades at $95.68 (market cap $53.47B). The key difference: Merck & Co., Inc. is far larger — about 6.1× Nasdaq Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.56%). Which is the better fit depends on your goals.
| MRK | NDAQ | |
|---|---|---|
Market Cap | $327.94B | $53.47B |
Sector | Health | Financials |
52-Week High | $132.93 | $100.98 |
52-Week Low | $77.60 | $76.85 |
Enterprise Value | $374.70B | $59.93B |
Dividend Yield | 2.56% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, net income was $18.25B, and the P/E ratio stands at 104.34. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook: Merck's acquisition strategy and consistent dividend payments ($0.85 per share) support a positive view, with analyst consensus price target at $140.58. Risks include high valuation multiples and competitive pressures in pharmaceuticals. Institutional holdings show increased interest, but investors should monitor integration of acquisitions and patent expirations.
Nasdaq (NDAQ) trades at $95.92, up 0.31% on the day, with a bullish technical signal from moving averages and strong support at $95. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding expectations, and revenue growth accelerated to $8.26 billion in 2025. Recent news includes the acquisition of LeveL Markets, advancing its always-on markets strategy.
The outlook is positive, supported by analyst consensus of $109.20 price target and 61% buy ratings. Key opportunities include sustained revenue growth and strategic acquisitions, while risks involve competitive pressures and market volatility. The stock offers a dividend yield with recent payouts of $0.31 per share.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
